NYSE · BDXHealthcareSurgical Instruments

Becton, Dickinson and financials

$181.97−1.01%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ3 '26
Jun 30
Q2 '26
Mar 31
Q1 '26
Dec 31
Q4 '25
Sep 30
Q3 '25
Jun 30
Q2 '25
Mar 31
Q1 '25
Dec 31
Q4 '24
Sep 30
Q3 '24
Jun 30
Q2 '24
Mar 31
Q1 '24
Dec 31
Q4 '23
Sep 30
Revenue$4.98B$4.71B$5.25B$5.89B$4.73B$4.48B$5.17B$5.44B$4.99B$5.04B$4.71B$5.09B
Gross profit$2.31B$2.15B$2.41B$2.80B$2.23B$1.86B$2.23B$2.49B$2.31B$2.30B$2.03B$1.70B
Gross margin46.5%45.7%45.9%47.5%47.3%41.5%43.2%45.7%46.2%45.7%43.1%33.4%
Operating income$663.0M$93.0M$601.0M$981.0M$739.0M$384.0M$482.0M$759.0M$700.0M$734.0M$438.0M$347.0M
Net income$377.0M-$311.0M$382.0M$493.0M$574.0M$308.0M$303.0M$400.0M$487.0M$537.0M$281.0M$108.0M
Net margin7.6%−6.6%7.3%8.4%12.1%6.9%5.9%7.4%9.8%10.6%6.0%2.1%
Diluted EPS$1.37$-1.11$1.34$1.71$2.00$1.07$1.04$1.36$1.68$1.85$0.96$0.37
EBITDA$1.31B$1.15B$1.33B$1.74B$1.41B$1.00B$1.18B$1.51B$1.38B$1.41B$999.0M$485.0M
Operating cash flow$577.0M$673.0M$656.0M$1.35B$1.59B-$205.0M$693.0M$1.18B$1.26B$514.0M$841.0M$1.32B
Free cash flow$434.0M$548.0M$548.0M$1.00B$1.42B-$319.0M$588.0M$882.0M$1.09B$380.0M$725.0M$1.03B
Diluted shares275.2M280.6M285.8M288.7M287.2M287.7M290.4M293.3M290.3M290.3M290.1M294.6M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30Jun 30Mar 31
Cash & equivalents$708.0M$813.0M$740.0M$567.0M$735.0M$667.0M
Short-term investments$1.0M$3.0M$11.0M$8.0M$22.0M$16.0M
Total debt$16.81B$17.28B$19.54B$19.18B$19.34B$19.27B
Total assets$50.73B$50.83B$54.84B$55.33B$54.90B$54.47B
Total liabilities$26.32B$26.70B$29.56B$29.93B$29.43B$29.23B
Shareholders' equity$24.42B$24.13B$25.28B$25.39B$25.47B$25.24B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology